|
Gene: SLC22A31 |
Gene summary for SLC22A31 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC22A31 | Gene ID | 146429 |
Gene name | solute carrier family 22 member 31 | |
Gene Alias | SLC22A31 | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
146429 | SLC22A31 | TD9 | Human | Lung | IAC | 2.44e-07 | 6.35e-01 | 0.088 |
146429 | SLC22A31 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 2.70e-02 | 6.76e-01 | -0.1406 |
146429 | SLC22A31 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.01e-03 | 6.18e-01 | -0.1408 |
146429 | SLC22A31 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 5.75e-05 | 9.58e-01 | -0.138 |
146429 | SLC22A31 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 7.46e-15 | 5.60e-01 | -0.2116 |
146429 | SLC22A31 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.01e-05 | 4.60e-01 | -0.1941 |
146429 | SLC22A31 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.17e-05 | 4.02e-01 | -0.2107 |
146429 | SLC22A31 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 3.23e-08 | 4.85e-01 | -0.2119 |
146429 | SLC22A31 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.98e-05 | 8.95e-02 | -0.0166 |
146429 | SLC22A31 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.37e-08 | 1.68e-01 | -0.0132 |
146429 | SLC22A31 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 9.27e-09 | 9.45e-02 | -0.013 |
146429 | SLC22A31 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.56e-06 | 9.21e-02 | -0.0121 |
146429 | SLC22A31 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 9.01e-04 | 7.40e-01 | -0.1284 |
146429 | SLC22A31 | male-WTA | Human | Thyroid | PTC | 5.37e-18 | 2.45e-01 | 0.1037 |
146429 | SLC22A31 | female-WTA | Human | Thyroid | PTC | 2.08e-02 | 2.53e-01 | 0.0726 |
146429 | SLC22A31 | PTC01 | Human | Thyroid | PTC | 4.60e-30 | 6.56e-01 | 0.1899 |
146429 | SLC22A31 | PTC03 | Human | Thyroid | PTC | 9.50e-07 | 2.71e-01 | 0.1784 |
146429 | SLC22A31 | PTC04 | Human | Thyroid | PTC | 6.62e-35 | 6.64e-01 | 0.1927 |
146429 | SLC22A31 | PTC05 | Human | Thyroid | PTC | 1.60e-40 | 1.37e+00 | 0.2065 |
146429 | SLC22A31 | PTC06 | Human | Thyroid | PTC | 5.43e-72 | 1.47e+00 | 0.2057 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | |
Breast | IDC | |
Breast | DCIS | |
Cervix | CC | |
Cervix | HSIL_HPV |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC22A31 | SNV | Missense_Mutation | rs777764468 | c.956N>C | p.His319Pro | p.H319P | protein_coding | deleterious(0.03) | possibly_damaging(0.895) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.928N>A | p.Leu310Ile | p.L310I | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.478N>C | p.Glu160Gln | p.E160Q | protein_coding | tolerated(0.09) | possibly_damaging(0.606) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.457T>C | p.Tyr153His | p.Y153H | protein_coding | deleterious(0.04) | benign(0.19) | TCGA-AJ-A3EJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
SLC22A31 | SNV | Missense_Mutation | rs764006054 | c.820G>A | p.Ala274Thr | p.A274T | protein_coding | tolerated(0.23) | benign(0.075) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.73C>T | p.Arg25Cys | p.R25C | protein_coding | deleterious(0.03) | benign(0.157) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC22A31 | SNV | Missense_Mutation | rs373504039 | c.344G>A | p.Arg115Gln | p.R115Q | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.356G>T | p.Arg119Ile | p.R119I | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
SLC22A31 | SNV | Missense_Mutation | novel | c.653N>A | p.Arg218Gln | p.R218Q | protein_coding | tolerated(1) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC22A31 | SNV | Missense_Mutation | rs565200064 | c.419N>A | p.Arg140His | p.R140H | protein_coding | tolerated(0.13) | benign(0.03) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |